30 participants
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-17
- Start Date:
- 2021-01-29
- Completion:
- 2026-12-02
Conditions
- Metastatic Lung Non-Small Cell Carcinoma
- Refractory Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
Interventions
- BIOLOGICAL
- DRUG
- OTHER
No Results Yet